HomePfizer and Blackstone Life Sciences announce strategic funding agreement for obesity programme

Pfizer and Blackstone Life Sciences announce strategic funding agreement for obesity programme

Pfizer Inc and Blackstone Life Sciences have announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a total of $1.5 billion of development costs through 2028 for berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions.

In exchange for the funding, Blackstone will be eligible to receive milestone-based payments, subject to US regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management, and achievement of certain commercial sales milestones.

Any milestone payments, if earned, will be payable to Blackstone over a multi-year period.

Under the agreement, Blackstone does not acquire any rights or ownership in berobenatide, and Pfizer retains full operational control and decision-making with respect to the berobenatide programme. Funds managed by Blackstone’s perpetual private equity strategy (BXPE) will invest alongside funds managed by Blackstone Life Sciences as part of the transaction.

- Advertisment -
- Advertisment -
- Advertisment -

Most Popular

Popular categories